Bulk Liposomal Urolithin A Powder Supplier in China

Liposomal Urolithin A is Urolithin A incorporated into microscopic phospholipid vesicles called liposomes. This lipid-based delivery system is designed to improve the aqueous dispersion, digestive stability and bioaccessibility of poorly water-soluble Urolithin A. It is also called Urolithin A liposome powder, nano-liposomal Urolithin A or phospholipid-encapsulated UroA.

The active Urolithin A molecule has CAS No. 1143-70-0, molecular formula C₁₃H₈O₄ and molecular weight 228.20 g/mol. Liposomal Urolithin A Powder is a formulation containing Urolithin A and phospholipids, so the complete ingredient does not have one separate CAS number or molecular formula.

Both products deliver the same active compound. Regular Urolithin A is supplied without a liposomal carrier, whereas Liposomal Urolithin A associates the active molecule with phospholipid vesicles. Liposomal technology is intended to improve dispersion, gastrointestinal stability and formulation flexibility; it does not change the chemical identity of Urolithin A.

Urolithin A has very low water solubility, which can cause poor aqueous dispersion, sedimentation and inconsistent distribution in liquid formulations. Liposome encapsulation helps incorporate UroA into a phospholipid-based delivery system suitable for advanced capsules, sachets, drink powders and liquid supplements.

Yes, but this is also true of regular Urolithin A supplements. Both deliver Urolithin A directly and do not require gut bacteria to convert ellagitannins or ellagic acid from pomegranates, walnuts and berries. The additional purpose of liposomal delivery is improved formulation performance—not microbiome independence itself.

Yes, but this is also true of regular Urolithin A supplements. Both deliver Urolithin A directly and do not require gut bacteria to convert ellagitannins or ellagic acid from pomegranates, walnuts and berries. The additional purpose of liposomal delivery is improved formulation performance—not microbiome independence itself.

Preclinical evidence suggests that well-designed Urolithin A liposomes can improve bioaccessibility and systemic exposure. However, performance depends on particle size, phospholipid composition, encapsulation efficiency, stability and manufacturing technology. No published head-to-head human trial identified as of July 2026 has confirmed that every liposomal formulation is better absorbed than regular Urolithin A.

Published human studies have evaluated conventional oral Urolithin A, not ProVita’s Liposomal Urolithin A Powder or a direct liposomal-versus-regular comparison. Human research supports the safety, systemic exposure and biological activity of standard Urolithin A, but those results cannot automatically be presented as clinical proof for a liposomal formulation. Relevant trials include Andreux et al., 2019, Liu et al., 2022 and Singh et al., 2022.

Recent preclinical research includes:

• A 2026 study found that gum-arabic-coated Urolithin A liposomes produced 3.09-fold higher relative oral bioavailability than free Urolithin A in an animal model. Zhang et al., 2026
• A 2024 study reported that gum-arabic-coated liposomes achieved 1.67 times the bioaccessibility of uncoated Urolithin A liposomes. Hu et al., 2024
• A 2023 rat study reported bioaccessibility of 79.6% for pH-driven liposomes, compared with 48.6% for thin-film liposomes and 25.3% for free Urolithin A. Hu et al., 2023

These formulations differ from ProVita’s sunflower-lecithin LULA-50%, so their results should not be treated as interchangeable product claims.

The submitted animal pharmacokinetic report used 12 male Sprague-Dawley rats divided into two groups of six. After a single oral dose, the regular Urolithin A control recorded an AUC₀–₁₂ₕ of 13.33 ± 2.93 µg·h/mL, while LULA-50% recorded 16.87 ± 3.02 µg·h/mL. The report calculated dose-normalized relative bioavailability of 12.65 ± 3.58.

No. The raw AUC ratio is approximately 1.27, not 12.65. The larger figure is a dose-normalized relative-bioavailability calculation based on different administered formulation doses: 500 mg/kg for the control and 50 mg/kg for LULA-50%. Because LULA-50% contains approximately 50% active Urolithin A, the active-equivalent normalization should be confirmed with the testing laboratory. It is also an animal result, not a human clinical claim.

ProVita’s LULA-50% specification is 50.0%–55.0% Urolithin A by HPLC. Representative batch LULA260201 tested at 54.17%. The remaining formulation primarily includes the sunflower-lecithin phospholipid delivery system.

A representative nanoparticle-size report recorded an average particle size of 144.64 nm and an average polydispersity index of 0.092 across three measurements. The individual particle-size results were 156.64 nm, 144.94 nm and 132.34 nm. Particle size and PDI should be verified on the relevant production batch.

Encapsulation efficiency, or EE%, measures the proportion of Urolithin A associated with or retained inside the tested liposomal fraction relative to the total Urolithin A added. It is different from the total Urolithin A assay and should be verified using a defined analytical method.

The submitted EffePharm membrane-filtration and HPLC report measured 48.07% ± 0.72% encapsulation efficiency for representative LULA-50% batch LULA250501. This is formulation-specific data and should not be applied automatically to every production batch.

No. Assay indicates how much total Urolithin A is present in the powder, while encapsulation efficiency indicates what proportion of that active compound is associated with the measured liposomal fraction. A product may have a high Urolithin A assay but comparatively low encapsulation efficiency.

The submitted comparison found 48.07% ± 0.72% EE for LULA-50% and 16.45% ± 1.32% EE for LULA-70%. The report attributes the higher LULA-50% result to its larger phospholipid-to-Urolithin A ratio. Therefore, higher nominal active content does not necessarily mean better liposomal performance.

The manufacturing process uses sunflower lecithin, food-grade ethanol and purified water to prepare a homogeneous phospholipid emulsion. This is followed by high-pressure homogenization, Urolithin A loading, freeze-drying, grinding, sieving, blending and final QA/QC approval. The lyophilized process converts the liposomal dispersion into a stable dry powder.

Representative COA specifications include:

• Urolithin A: 50.0%–55.0% by HPLC
• Moisture: ≤5.0% by Karl Fischer
• Lead: ≤0.5 ppm by ICP-MS
• Arsenic: ≤0.5 ppm by ICP-MS
• Cadmium: ≤0.5 ppm by ICP-MS
• Mercury: ≤0.1 ppm by ICP-MS
• Total plate count: ≤1,000 CFU/g
• Yeast and mold: ≤100 CFU/g
• Salmonella, E. coli and Staphylococcus: negative

Microbiological testing follows the stated USP-NF 2024 methods.

Liposomal Urolithin A is suitable for healthy-aging supplements, mitochondrial-health formulas, active-aging products, sports nutrition, muscle-support supplements, capsules, tablets, sachets, stick packs and drink powders. Liquid and beverage applications require finished-product dispersion and stability testing.

FDA GRAS Notice 791 covers a specific notified Urolithin A ingredient and stated food uses at defined levels; it does not automatically establish GRAS status for every liposomal formulation. Regulatory status also differs among the United States, European Union, United Kingdom, Canada and other markets. Buyers should complete a market-specific review of the exact Urolithin A source, phospholipid carrier, dosage and intended application. FDA GRN 791

Yes. ProVita Biotech supplies bulk Liposomal Urolithin A Powder to supplement manufacturers, brands and distributors. We support qualified B2B customers with samples, wholesale quotations, formulation development, capsules, tablets, sachets, private-label packaging and customized liposomal delivery solutions. MOQ, lead time, packaging and current GMP, Kosher or Halal certificate availability should be confirmed before ordering.